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Abstract
Purpose To investigate the clinical value of 18F-fluorocho-
line PET/CT (CH-PET/CT) in treatment decisions in
patients with recurrent prostate cancer (rPCA).
Methods The study was a retrospective evaluation of 156
patients with rPCA and CH-PET/CT for restaging. Ques-
tionnaires for each examination were sent to the referring
physicians 14–64 months after examination. Questions in-
cluded information regarding initial extent of disease,
curative first-line treatment, and the treatment plan before
and after CH-PET/CT. Additionally, PSA values at diagno-
sis, after initial treatment, before CH-PET/CT and at the end
of follow-up were also obtained from the questionnaires.
Results Mean follow-up was 42 months. The mean Gleason
score was 6.9 at initial diagnosis. Initial treatment was:
radical prostatectomy in 110 patients, radiotherapy in 39,
and combined prostatectomy and radiotherapy in 7. Median
PSA values before CH-PET/CT and at the end of follow-up
were 3.40 ng/ml and 0.91 ng/ml. PSA levels remained
stable, decreased or were below measurable levels in 108
patients. PSA levels increased in 48 patients. In 75 of the
156 patients (48%) the treatment plan was changed due to
the CH-PET/CT findings. In 33 patients the therapeutic plan
was changed from palliative treatment to treatment with
curative intent. In 15 patients treatment was changed from
curative to palliative. In 8 patients treatment was changed
from curative to another strategy and in 2 patients from one
palliative strategy to another. In 17 patients the treatment
plan was adapted.
Conclusion CH-PET/CT has an important impact on the
therapeutic strategy in patients with rPCA and can help to
determine an appropriate treatment.
Keywords 18F-CholinePET/CT. Recurrent prostate cancer .
Clinical impact
Introduction
Adenocarcinoma of the prostate (PCA) is the most common
malignant tumour in men in the United States, and is asso-
ciated with the second highest number of cancer deaths per
year following bronchial carcinoma [1]. Nevertheless, cur-
rent staging and restaging procedures especially regarding
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nodal involvement and distant metastases still have many
limitations, leading to insufficiencies in treatments with
curative intent. Consequently as many as 19–53% of
patients initially treated with curative intent suffer from
recurrent disease [2–5]. Rising levels of prostate-specific
antigen (PSA) in the blood serum of patients indicate tu-
mour progression, often long before imaging modalities can
detect any abnormalities. In this biochemical relapse situa-
tion there are no guidelines giving any conclusive sugges-
tions regarding imaging procedures. Bone scintigraphy and
CT are both insensitive and show reliable results only at
PSA levels of above 20 ng/ml [6]. Thus, according to the
current guidelines, these examinations can safely be omit-
ted. Depending solely on the kinetics of the rising PSA
levels the decision is made whether a local recurrence or a
distant recurrence is present. If a local recurrence is sus-
pected patients may qualify for a salvage procedure of the
prostate fossa. If distant disease is suspected only palliative
antihormonal treatment is suggested. MRI with an endorec-
tal coil shows reliable results in the evaluation of the pros-
tate fossa, but is not routinely recommended by the
guidelines [6–8].
18F-Choline PET/CT (CH-PET/CT) is a promising ex-
amination tool for the detection of recurrent PCA (rPCA)
[9]. Even though the exact role of the examination is still a
matter of discussion, it seems that CH-PET/CT starts play-
ing a role in the management of patients with biochemical
relapse [10, 11]. Several studies have demonstrated that CH-
PET/CT labelled with either 11C [12, 13] or with 18F [14,
15] can detect tumour recurrence at PSA levels of above
2 ng/ml, giving the opportunity for a salvage procedure with
curative intent at an early time point of the recurrence
[12–15]. In certain constellations, tumour recurrence can
even be detected if PSA levels are below 2 ng/ml, but the
detection rate in these patients is only approximately 30–
40% [13, 16]. Even though localized treatment of distant
metastases is currently not an established therapy, several
studies of CH-PET/CT-guided radiation therapy and salvage
surgery have already been published with promising results
[17–19]. We therefore retrospectively analysed the impact of
the results of CH-PET/CT examinations performed at our
institution on treatment decisions.
Materials and methods
This study was conducted according to the local ethics
committee guidelines for retrospective analyses. Between
March 2003 and October 2007, we performed 353 CH-
PET/CT examinations in patients with PCA. Of these
patients, 229 had rising PSA levels after initial treatment
with surgery, radiation therapy or both, indicating recurrent
disease. Since no recommendations were given by the
guidelines, previous conventional imaging (e.g. bone scan,
MRI, CT) was not required for inclusion in our follow-up
study [6–8]. Questionnaires were created and sent to the
referring physicians in December 2008, 14 months after
the scan of the last included patient. After a waiting
period of approximately 4 weeks, those physicians who
had not returned the questionnaires were reminded once
by telephone.
CH-PET/CT
All the data were acquired on a combined PET/CT in-line
system (Discovery LS or Discovery ST; GE Health Systems,
Milwaukee, WI). These dedicated integrated systems com-
prise a PET scanner (GE Advance Nxi) and a multislice
helical CT scanner (LightSpeed plus or LightSpeed 16), and
acquire coregistered CT and PET images in one session. No
oral or intravenous CT contrast agent was used. Patients
were examined in the supine position. The unenhanced CT
scans were acquired with the following parameters: 80 mA,
140 kV, 0.5 s tube rotation, 4.25 mm section thickness,
867 mm scan length, and 22.5 second data acquisition time.
The CT scans were acquired during breath-hold in the nor-
mal expiration position, and scanning included the area from
the head to the pelvic floor. The PET emission scan started
3–4 min after injection of a standard dose of 200–300 MBq
18F-fluorocholine. After acquisition of a partial body
scan (pelvic floor to vertex), approximately 15–
20 min after injection a second partial body scan with
the same scan length was acquired, without taking the
patient off the examination table and without voiding
of the bladder. The PET images were acquired starting
at the level of the pelvis, with an acquisition time of
3 min for the emission scan per cradle position and a
one-slice overlap. The CT data were used for attenua-
tion correction, and images were reconstructed using a
standard 2-D iterative algorithm (ordered subsets ex-
pectation maximization).
For image fusion, 4.25-mm thick CT image slices were
reconstructed. Images were then transferred to a commer-
cially available workstation (GE Advantage). These work-
stations allow simultaneous data evaluation of early- and
late-phase PET studies with the corresponding CT images as
a single procedure and in image fusion mode. Both partial
body PET scans were fused with the CT scan and read side
by side. The early scan was primarily used for the evaluation
of the prostate fossa because at this time the tracer would not
have arrived in the bladder. The late scan was used for better
differentiation between reactive/Inflammatory and malig-
nant lymph nodes [20]. A visually detectable washout of
the tracer from lymph nodes over time was considered as
benign, whereas a persisting or increasing tracer activity in
the lymph nodes was considered as a sign for malignancy.
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Diagnostic findings
All CH-PET/CT examinations were reported by a dual board-
certified radiologist/nuclear medicine physician with 5 years
of experience in CH-PET/CT reading. The findings from each
CH-PET/CT examination were collected from these written
reports. Although performed in some patients, validation of
the findings from CH-PET/CTwith other imaging methods or
with a histological work-up could not be obtained consistently
due to the retrospective nature of the study, and was therefore
not required for inclusion in the study.
Questionnaire
The questionnaire consisted of questions regarding the fol-
lowing topics:
1. Initial TNM stage and initial grading according to
Gleason
2. Initial therapies and antihormonal treatments
3. Treatment after CH-PET/CT and hypothetical treatment
if no CH-PET/CT had been available
4. PSAvalues at diagnosis, after initial therapy, before CH-
PET/CT and at the end of follow-up
The referring physicians were asked to indicate the ther-
apeutic strategy in the patient as it had been defined after the
CH-PET/CT. Then they were asked to define a hypothetical
therapeutic strategy assuming the results of the CH-PET/CT
had not been available. Additionally, they were asked to
indicate whether the chosen treatment plan had been influ-
enced by the CH-PET/CT scan. A change in therapy con-
sisted of the choice of a different therapeutic strategy (e.g.
antihormonal therapy to radiation therapy) or of an
alteration within a therapeutic strategy (e.g. adaptation of
the radiation field).
Statistical analysis
General descriptive statistics were used to calculate mean
age, mean follow-up time and median PSA values. Due to
the substantial skew of the PSA value distribution, logarith-
mic transformation was performed for all PSA values to
obtain a symmetric distribution. A constant value of 0.01
was added to all PSA values before transformation to make
values of zero valid for transformation. PSA ratios from
PSA values before and after CH-PET/CT were calculated
by subtracting the log-transformed values from after CH-
PET/CT from the log-transformed values from before CH-
PET/CT. Nonparametric testing (Mann-Whitney U test) was
used to compare PSA ratios among different patient sub-
groups. The Wilcoxon signed ranks test was used for com-
parison of PSA values before and after CH-PET/CT. P
values <0.05 were considered significant. All statistical
analyses were performed using SPSS for Windows, release
18.0.0 (SPSS, Chicago, IL)
Results
Disease characteristics
A total of 163 questionnaires were returned by the referring
physicians. Seven patients with returned questionnaires had
to be excluded because of missing PSA values before CH-
PET/CT and/or at the end of follow-up. Finally, 156 of 229
completed questionnaires (68%) were evaluated (Fig. 1).
353 PCA-patients CH-PET/CT
between March 2003 - October 2007
229 patients rPCA with rising PSA after
surgery and/or radiation therapy
Questionnaires to referring physicians
14-64 months after examination
Questionnaires returned by referring
physicians: 163 patients
Questionnaires without missing relevant
data: 156 patients
Fig. 1 Patient inclusion
pathway
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The mean follow-up was 42 months (range 14–64 months).
The mean age of the patients at the time of CH-PET/CTwas
66 years (range 48–81 years). At diagnosis the most fre-
quent tumour stage was T3 N0 M0 (Table 1), and the mean
Gleason score was 6.91. The most frequently represented
gleason scores were Gleason 7 (n=52), Gleason 6 (n=38)
and Gleason 8 (=27) (Fig. 2). Initial treatment consisted of
radical prostatectomy in 110 patients, radiotherapy in 39
patients and a combination of both in 7 patients.
Diagnostic performance
Positive findings on CH-PET/CT were reported in 124 of
the 156 patients (79%): 63 patients (40%) had a local
recurrence only, 27 patients (17%) had lymphatic metastases
only, and 9 patients (6%) had metastases to the bones only,
14 patients (8%), had a local recurrence plus nodal metas-
tases, 8 patients (5%) had local recurrence plus bony metas-
tases, and 4 patients (3%) had tumour manifestations in the
prostate fossa, lymph nodes and bones.
Actual vs. hypothetical treatment
In 75/156 patients (48%) the treatment plan was changed. In
33 patients (21%) treatment was changed from palliative
treatment to treatment with curative intent (surgery, radiation
therapy, high-intensity focused ultrasound and combined ther-
apies). In 15 patients (10%) treatment was altered from cura-
tive to palliative (watchful waiting, antihormonal treatment or
chemotherapy). In 8 patients (5%) treatment was changed
from one curative modality to another and in 2 patients (1%)
from one palliative modality to another. In 17 patients (11%)
the treatment plan was adapted (Table 2). In 8 patients (6%) a
change in treatment was indicated even though CH-PET/CT
showed no abnormities. In three of these patients (initially
operated upon) who were scheduled for radiotherapy before
CH-PET/CT, the radiation field was adapted. In one patient
(initially operated upon) radiotherapy was changed to surgery.
In one patient (initially operated upon) who was scheduled for
surgery, the surgical procedure was adapted. In one patient
Table 1 TNM stages of our patients. Patients with MX were treated as
M0 in this table. Five patients had distant metastases (three patients
T3 N1 M1, one patient T4 N0 M1, and one patient T4 Nx M1)
T stage N0 N1 Nx M1
1 14 0 0 0
2 52 5 6 0
3 61 6 6 3
4 2 2 1 2
x 0 0 1 0
n=1; (1%)
n=2; (1%)
n=8; (5%)
n=38; (23%)
n=52; (32%)
n=27; (17%)
n=17; (10%)
n=1; (1%)
n=12; (7%) n=5; (3%)
Gleason 2
Gleason 3
Gleason 4
Gleason 5
Gleason 6
Gleason 7
Gleason 8
Gleason 9
Gleason 10
Gleason x
Fig. 2 The distribution of Gleason scores
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(initially operated upon) who was scheduled for radiotherapy
and additional antihormonal treatment, the strategy was
changed to antihormonal treatment only. In one patient (ini-
tially treated with radiotherapy) antihormonal treatment was
changed to watchful waiting. In one patient (initially operated
upon) scheduled for antihormonal treatment this treatment
was adapted.
PSA values
Table 3 presents the PSA values in our patients at the
different time-points. Since two patients had extraordinarily
high PSA values at the end of follow-up (150 ng/ml in one,
and 334.8 ng/ml in the other), median PSA values were
calculated as well as mean values in order to correct for
the overwhelming influence of these two patients’ values on
the results. PSA levels before CH-PET/CT were significant-
ly higher than those at the end of follow-up (P<0.001;
Wilcoxon signed ranks test). At the end of follow-up, PSA
values had declined in 107 patients (69%) due to subsequent
therapies. Of these 107 patients, 16 (10%) had values below
the measurable threshold, 1 (1%) had a stable PSAvalue and
48 (31%) showed increased PSA levels.
PSA values before CH-PET/CT were significantly higher
(P<0.001, Mann-Whitney U test) in patients with a positive
CH-PET/CT scan (median PSA 4.50 ng/ml, range 0.15–
296.61 ng/ml) than in those with a negative scan (median
PSA 1.20 ng/ml, range 0.1–30.3 ng/ml). However, there was
no significant difference in the PSA ratios before and after
CH-PET/CT between patients with a positive CH-PET/CT
scan and those with a negative scan (P00.70, Mann-
Whitney U test). These two groups did not differ regarding
initial PSA levels at the time of diagnosis (P00.48, Mann-
Whitney U test). There was also no significant difference in
the PSA ratios before and after CH-PET/CT between
patients in whom the intended treatment plan was changed
after CH-PET/CT (n075, 48%) and those in whom treat-
ment was not changed (n081, 52%; P00.68, Mann-
Whitney U test). Again the PSA values at the time of
primary diagnosis were not significantly different between
these two groups (P00.67, Mann-Whitney U test)
Discussion
To our knowledge this retrospective analysis is the first to
analyse the clinical impact of CH-PET/CT on treatment
decisions in patients with rPCA. We obtained our data using
questionnaires sent to those physicians who had referred
their patients for a CH-PET/CT scan to our institution. The
referring physicians were asked to provide information
about the therapy, which had been performed after CH-
PET/CT and to determine a hypothetical therapeutic man-
agement without the information obtained from the CH-
PET/CT scan. With this method we were able to demon-
strate a strong clinical impact of CH-PET/CT. The results of
our examination led to changes in the therapy in 48% of
patients, which consisted of adaptation of the current treat-
ment regimen or even complete change in the therapeutic
approach. Even though a comparison with a non-CH-PET/
CT control group was not possible due to the retrospective
study design, the therapies performed after CH-PET/CT
were effective since a significant decline in the mean PSA
values after the CH-PET/CT scan compared to before was
observed. The impact of CH-PET/CT on treatment decisions
is illustrated in Figs. 3 and 4. Figure 3 shows a patient in
Table 3 PSA values in our
patients (including the availabil-
ity of the measurements) at se-
lected time-points
At diagnosis Nadir after
treatment
Before
CH-PET/CT
End of
follow-up
No. of patients with value available 149/156 139/156 156/156 156/156
PSA (ng/ml)
Mean 22.18 0.72 9.46 9.50
Median 12.00 0.10 3.40 0.91
Table 2 Treatments with CH-PET/CT and hypothetical treatments without CH-PET/CT as indicated by the referring physicians
Watchful waiting
(no therapy)
Antihormonal
treatment
Radiation
therapy
Surgery High-intensity
focused
ultrasound
Chemotherapy Antihormonal
and radiation
therapy
Surgery and
radiation
therapy
Therapy with
CH-PET/CT
19 37 59 11 6 1 22 1
Hypothetical therapy
without CH-PET/CT
22 54 60 4 2 0 14 0
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whom CH-PET/CT showed bone metastasis leading to a
change in treatment/management, and Fig. 4 shows a patient
in whom CH-PET/CT confirmed local recurrence so that
treatment/management was not changed.
Interestingly PSA ratios in patients with positive findings
on CH-PET/CT were not significantly different from those
in patients with negative findings, as was also the case in
patients with therapeutic changes due to CH-PET/CT com-
pared to those without. We believe that there are several
factors which lead to these results. If patients had no find-
ings on CH-PET/CT, the treatment in general followed the
standard procedures for recurrent disease [6–8]. According
to the guidelines in such a situation, if no other findings are
present the decision whether a local or distant recurrence is
present is made on the basis of the PSA kinetics. The
standard procedures then are radiation therapy (if surgery
was performed initially), antihormonal treatment, salvage
resection, or combined approaches. After such a procedure
the likelihood of success is high, especially since CH-PET/
CT (even though per definition false-negative due to rising
PSA) has excluded gross metastatic spread. Thus it is not
surprising that not only those patients with positive findings
on CH-PET/CT but also those without detectable patholo-
gies on CH-PET/CT had favourable PSA ratios. The situa-
tion in the subgroup of patients with therapeutic changes
was quite similar to the situation in those without. If CH-
PET/CT confirmed the suspected localization of recurrent
Fig. 3 A 53-year-old patient 6 years after surgery. PSA increasing to
3.0 ng/ml. a Bone scintigraphy including SPECT/CT was read as
negative including the right iliac bone (arrow). Thus local recurrence
was suspected leading to a hypothetical treatment with radiation
therapy of the small pelvis. b CH-PET/CT performed 4 weeks later
revealed a metastasis in the iliac bone (arrows). The treatment plan was
changed to radiation therapy of the iliac bone and additional antihor-
monal treatment. PSA declined to 2.45 ng/ml
Fig. 4 A 74-year-old patient 3 years after surgery. PSA increasing to
2.2 ng/ml. CH-PET/CT confirmed clinically suspected local recur-
rence. There was no change in the treatment plan. The patient received
radiation therapy and the PSA declined to 0.43 ng/ml
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disease, no change in management occurred. The intended
treatment approach remained correctly unchanged in these
patients and the PSA ratios were of course as favourable as
they were in those patients in whom CH-PET/CT demon-
strated findings which led to a change in management.
Therefore, it is clear that with our study set-up it is not
possible to make statements about the influence of CH-
PET/CT on the outcome of rPCA.
Interestingly in eight patients the referring physicians
indicated changes in therapy even though CH-PET/CT
demonstrated no positive findings. These results can be
explained by the fact that despite the failure to detect
recurrent disease, CH-PET/CT was able to exclude gross
metastatic spread. This obviously led to changes in the
planned treatment such as adaptation of the radiation
field.
The major limitation of our study was its retrospective
character. Our referring physicians were asked to retrospec-
tively determine which therapy would have been performed
if no CH-PET/CT scan findings had been available. There
was potential bias, since the referring physicians were most
likely to support the use of CH-PET/CT. Thus more favour-
able results regarding therapeutic changes could be assumed
compared to a real prospective study design. Nevertheless,
we believe that no serious bias was introduced into our
study. First, according to the guidelines for PCA recurrence
the therapeutic options are not very wide. They consist of
radiation therapy, antihormonal treatment, salvage surgery,
chemotherapy or a combination of these. There were two
categories of patients referred for CH-PET/CT. The first
category consisted of patients who had had a complete
initial treatment with curative intent, recurrence and a sal-
vage procedure, and in whom the PSA level had again risen.
Following the guidelines in such a situation without further
diagnostics only a palliative procedure with antihormonal
treatment or watchful waiting would be advised. Any ther-
apy aside from these two options was therefore very likely
to be due to CH-PET/CT and a bias was basically only
possible if a change in therapy occurred within the two
palliative options, which was indicated in only 2 of 75
patients. The second category were patients whose PSA
did not decline sufficiently or started rising again after initial
curative therapy. In these potentially curable patients the
standard procedure according to the guidelines is a salvage
locoregional therapy mostly consisting of surgery or radia-
tion therapy. Thus the indicated therapeutic changes from a
curative to a palliative setting (15 of 75 patients) or within
the same curative modality, such as extended lymphadenec-
tomy or extended radiation field (16 of 75 patients), were
most likely correct and not due to bias. The only potential
for bias was in those patients in whom therapeutic changes
were indicated from one curative setting to another (8 of 75
patients).
Conclusion
In our patient population CH-PET/CT in patients with rPCA
had an important impact on the therapeutic strategy and was
able to help determine an appropriate treatment in these
patients.
Conflicts of interest None.
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